Stefano Barbi
Overview
Explore the profile of Stefano Barbi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1466
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borghini N, Lazzaretti M, Lunghi P, Malpeli G, Barbi S, Perris R
Cell Biosci
. 2025 Feb;
15(1):25.
PMID: 39980017
Proteoglycans are an ample family of complex extracellular matrix/cell surface components known to impact on virtually all biological processes that take place during life of a human being, in its...
2.
Malpeli G, Barbi S, Innamorati G, Alloggio M, Filippini F, Decimo I, et al.
J Pers Med
. 2022 Dec;
12(12).
PMID: 36556227
Loss of CDH1/Cadherin-1 is a common step towards the acquisition of an abnormal epithelial phenotype. In gastric cancer (GC), mutation and/or downregulation of CDH1/Cadherin-1 is recurrent in sporadic and hereditary...
3.
Simbolo M, Barbi S, Fassan M, Mafficini A, Ali G, Vicentini C, et al.
J Thorac Oncol
. 2019 May;
14(9):1651-1661.
PMID: 31085341
Introduction: DNA mutational profiling showed that atypical carcinoids (ACs) share alterations with large cell neuroendocrine carcinomas (LCNECs). Transcriptomic studies suggested that LCNECs are composed of two subtypes, one of which...
4.
Amato E, Mafficini A, Hirabayashi K, Lawlor R, Fassan M, Vicentini C, et al.
J Pathol
. 2018 Oct;
247(1):123-134.
PMID: 30306561
Solid pseudopapillary neoplasms (SPN) of the pancreas are rare, low-grade malignant neoplasms that metastasise to the liver or peritoneum in 10-15% of cases. They almost invariably present somatic activating mutations...
5.
Malpeli G, Barbi S, Tosadori G, Greco C, Zupo S, Pedron S, et al.
Oncotarget
. 2018 Jul;
9(51):29753-29771.
PMID: 30038718
In order to investigate the role of microRNAs in the pathogenesis of different B-cell lymhoma subtypes, we have applied an array-based assay to a series of 76 mixed non-Hodgkin B-cell...
6.
Noe M, Pea A, Luchini C, Felsenstein M, Barbi S, Bhaijee F, et al.
Mod Pathol
. 2018 Jun;
31(10):1532-1538.
PMID: 29849115
Neurofibromatosis type 1 (NF1) is a hereditary cancer predisposition syndrome characterized by frequent cutaneous and nervous system abnormalities. Patients with NF1 also have an increased prevalence of multiple gastrointestinal and...
7.
Malpeli G, Barbi S, Greco C, Zupo S, Bertolaso A, Scupoli M, et al.
Oncotarget
. 2018 May;
9(28):19961-19979.
PMID: 29731996
First line drug treatment of follicular lymphoma (FL) patients is followed by a highly variable disease-free time before relapse in about one third of patients. No molecular marker is able...
8.
Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P, et al.
Nature
. 2017 Sep;
550(7677):548.
PMID: 28953865
This corrects the article DOI: 10.1038/nature21063.
9.
Scarpa A, Chang D, Nones K, Corbo V, Patch A, Bailey P, et al.
Nature
. 2017 Feb;
543(7643):65-71.
PMID: 28199314
The diagnosis of pancreatic neuroendocrine tumours (PanNETs) is increasing owing to more sensitive detection methods, and this increase is creating challenges for clinical management. We performed whole-genome sequencing of 102...
10.
Malpeli G, Barbi S, Zupo S, Tosadori G, Scardoni G, Bertolaso A, et al.
Oncotarget
. 2017 Jan;
8(7):11809-11826.
PMID: 28107180
In the late B cell differentiation stages, miRNAs expression modifications promoting or inhibiting key pathways are only partially defined. We isolated 29 CD19+ human B cell samples at different stages...